Antisense Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANP.AX research report →
Price Chart
About the company
Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
- CEO
- James Garner MBA
- IPO
- 2001
- Employees
- 8
- HQ
- Toorak, VIC, AU
Get TickerSpark's AI analysis on ANP.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $52.29M
- P/E
- -1.34
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.00
- EV/EBITDA
- -0.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -65.33%
- ROIC
- -64.92%
Latest fiscal year · YoY change
- Revenue
- $1.58M-11.1%
- Gross Profit
- $1.55M-9.7%
- Op Income
- $-13,344,975
- Net Income
- $-11,379,828-95.1%
- EPS
- $-0.02-94.6%
- OCF Growth
- -4.4%
- FCF Growth
- -4.8%
- 52W High
- $0.11
- 52W Low
- $0.05
- 50D MA
- $0.06
- 200D MA
- $0.07
- Beta
- 1.06
- RSI (14)
- 45
- Avg Volume
- 548.97K
No earnings-call transcripts are available for ANP.AX yet.
- Free Float
- 66.7%
- Shares Outstanding
- 901.55M
- Float Shares
- 601.19M
Our ANP.AX coverage
Recent articles, reports, and earnings notes.
No research on ANP.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANP.AX report →